Shares of Cellectis S.A. (NASDAQ:CLLS – Get Free Report) have been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $5.46.
A number of analysts have commented on CLLS shares. Barclays downgraded shares of Cellectis from an “overweight” rating to an “underweight” rating and cut their price objective for the company from $9.00 to $1.30 in a report on Wednesday, September 16th. Wells Fargo & Company dropped their price objective on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Citizens Jmp cut shares of Cellectis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 15th. Finally, Robert W. Baird reduced their target price on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, September 15th.
Read Our Latest Analysis on CLLS
Institutional Investors Weigh In On Cellectis
Cellectis Price Performance
Shares of NASDAQ CLLS opened at $0.92 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 1.61. The firm has a market cap of $92.01 million, a P/E ratio of -0.72 and a beta of 3.21. Cellectis has a twelve month low of $0.88 and a twelve month high of $5.45. The company has a 50 day moving average of $1.23 and a 200 day moving average of $2.85.
Cellectis Company Profile
Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.
Read More
- Five stocks we like better than Cellectis
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
